Toussaint C, Dupont E, Vanherweghem J L, Cappel R, De Roy G, Vereerstraeten P, Kinnaert P, Thiry L, Van Geertruyden J
Adv Nephrol Necker Hosp. 1979;8:269-94.
Liver dysfunction was observed in 33% of patients treated by hemodialysis and kidney transplantation. Fifty-eight percent of these cases of hepatitis occurred in patients with past or present HBs antigenemia, and 77% of HBsAg-positive patients showed evidence of LD. However, during the course of a program conducted from 1969 to 1976 and involving 267 patients, the decrease in the prevalence of HBs antigenemia observed during the last two years did not lead to any reduction in LD incidence. In a small number of patients, potentially hepatotoxic drugs could be incriminated, but in our experience azathioprine never appeared to be involved. In a few patients, LD was due to granulomatous disease of the liver, such as tuberculosis and schistosomiasis. Twenty-one (7%) of the 267 patients at risk developed chronic hepatitis, which contributed to death in nine patients. In 12 cases (three deaths), this form of hepatitis occurred in HBsAg-positive patients, and in nine cases (six deaths), in HBsAg-negative patients. In three of these latter individuals, cytomegalovirus could be incriminated. Routine monthly screening for CMV in kidney recipients confirmed the high incidence of this viral infection in such patients. Studies on murine CMV infection have demonstrated that this infection can be enhanced by histoincompatible graft or by cyclophosphamide in a model that is very close to the kidney recipient. As in mice, CMV infection in kidney recipients apparently results from reactivation of a latent infection. It seems to play a major role in the LD observed and could apparently lead to chronic hepatitis and even to cirrhosis of the liver. Finally, the occurrence of LD in HBsAg-, anti-HBs- and antiCMV-negative patients would suggest the responsibility of other viruses for the pathogenesis of liver disease in patients treated by hemodialysis and kidney transplantation. Besides Epstein-Barr virus, other viruses, such as hepatitis C virus, should be thoroughly scrutinized.
在接受血液透析和肾移植治疗的患者中,33%出现了肝功能障碍。这些肝炎病例中有58%发生在既往或当前存在乙肝表面抗原血症的患者中,而77%的乙肝表面抗原阳性患者有肝功能障碍的证据。然而,在1969年至1976年开展的一项涉及267名患者的项目过程中,过去两年观察到的乙肝表面抗原血症患病率的下降并未导致肝功能障碍发生率的任何降低。在少数患者中,可能存在潜在肝毒性的药物,但根据我们的经验,硫唑嘌呤似乎从未涉及其中。在少数患者中,肝功能障碍是由肝脏肉芽肿性疾病引起的,如结核病和血吸虫病。267名有风险的患者中有21名(7%)发展为慢性肝炎,其中9名患者因此死亡。在12例(3例死亡)中,这种肝炎形式发生在乙肝表面抗原阳性患者中,在9例(6例死亡)中,发生在乙肝表面抗原阴性患者中。在后者中的3例中,可归咎于巨细胞病毒。对肾移植受者进行每月一次的巨细胞病毒常规筛查证实了此类患者中这种病毒感染的高发生率。对小鼠巨细胞病毒感染的研究表明,在一个与肾移植受者非常相似的模型中,这种感染可因组织不相容移植或环磷酰胺而增强。与小鼠一样,肾移植受者中的巨细胞病毒感染显然是由潜伏感染的重新激活引起的。它似乎在观察到的肝功能障碍中起主要作用,显然可能导致慢性肝炎甚至肝硬化。最后,在乙肝表面抗原、抗乙肝表面抗体和抗巨细胞病毒均为阴性的患者中出现肝功能障碍,这表明其他病毒可能与血液透析和肾移植治疗患者肝病的发病机制有关。除了爱泼斯坦 - 巴尔病毒外,其他病毒,如丙型肝炎病毒,也应进行彻底审查。